Rev. Soc. Esp. Dolor. 2021; 28(4): 242-245 / DOI: 10.20986/resed.2021.3924/2021
Susana Bella, Marta Bonet, Alejandra Mira, Mireia Duart, Vicente Moreno, Pilar Sala
ABSTRACT
Brachial plexus schwannomas are tumors developed from the neural sheaths of rare presentation, but benign evolution. They can cause symptoms, generally of the neuropathic type, due to local growth with the consequent compressive effect of noble neural structures such as the roots of the brachial plexus.
Botulinum toxin is a neurotoxin synthesized by the bacterium Clostridium Botulinum. Its mechanism of action consists of selectively blocking the cholinergic receptors of the neuromuscular junction, producing a temporary and reversible neuromuscular paralysis, recovering function in approximately three to six months.
We present the case of a patient diagnosed with brachial plexus schwannoma with increasing compressive effect who was treated with botulinum toxin in the scalene muscles.
RESUMEN
Los schwannomas de plexo braquial son tumoraciones desarrolladas a partir de las vainas neurales de rara presentación, pero evolución benigna. Pueden ocasionar clínica, generalmente de tipo neuropático, por crecimiento local con el consiguiente efecto compresivo de estructuras neurales nobles como las raíces del plexo braquial.
La toxina botulínica es una neurotoxina sintetizada por la bacteria clostridium botulinum. Su mecanismo de acción consiste en bloquear selectivamente los receptores colinérgicos de la unión neuromuscular, produciendo una parálisis neuromuscular temporal y reversible, recuperando la función en aproximadamente tres a seis meses.
Presentamos el caso de un paciente diagnosticado de schwannoma de plexo braquial con efecto compresivo creciente, a quien se le plantea tratamiento con toxina botulínica en los músculos escalenos.
Nuevo comentario
Comentarios
No comments in this article
Bibliografía
1. Lee HJ, Kim JH, Rhee SH, Gong HS, Baek GH. Is Surgery for Brachial Plexus Schwannomas Safe and Effective?. Clin Orthop Relat Res. 2014;472(6):1893-8.
2. Vučemilo L, Lajtman Z, Mihalj J, Plašćak J, Lakušić DM, Mužinić D. Brachial plexus schwannoma- Case report and literature. Acta Clin Croat. 2018;57(2):366-71.
3. Chan JSY, Josephine WYI. Brachial Plexus Schwannoma: Report of 4 cases with Intralesional Enucleation. J Clin Case Rep. 2017;7(12):1052.
4. Ahmadi A Hirbod, H, Cheraghipoor M, Izadi F. Schwannoma of the Brachial Plexus Presented as a Neck Mass: A Case Report and Review of the Literature. Int J Otolaryngol Head Neck Surg. 2015;4(2):104-7. DOI: 10.4236/ijohns.2015.42019.
5. Rashid M, Salahuddin O, Yousaf S, Qazi UA, Yousaf K. Schwannoma of the brachial plexus; report of two cases involving the C7 root. J Brachial Plex Peripher Nerve Inj. 2013;8(1):12.
6. Munireddy MV, Pavan BK, Bhaskaran A. Schwannoma of brachial plexus presenting as supraclavicular mass: A rare presentation, evaluation and its management is a challenge to surgeons. J Med Sci Clinical Res. 2017;5(8):26114-7.
7. Yun DH, Kim HS, Chon J, Lee J, Jung PK. Thoracic Outlet Syndrome Caused by Schwannoma of Brachial Plexus Ann Rehabil Med. 2013;37(6):896-900.
8. Reynoso R. Síndrome de la salida torácica neurogénica. Revisión etiopatológica. Serie de casos. Ortho-tips 2012;8(1):37-48.
9. Quintana J, Mirabal Y, Lacerda AJ. Síndrome de la salida torácica. Actualización y revisión del tema. MEDICIEGO 2016;22(1):70-5.
10. Woo Lee G, Ho Kwon Y, Ho Jeong J, Won Kim J. The efficacy of scalene Injection in Thoracic Outlet Syndrome. J Korean Neurosurg Soc. 2011;50(1):36-9.
11. Jordan S, Ahn S, Freischlag J, Gelabert HA, Machleder HI. Selective Botulinum Chemodenervation of the Scalene Muscles for Treatment of Neurogenic Thoracic Outlet Syndrome. Ann Vasc Surg. 2000;14(4):365-9.
12. Foley JM, Finlayson HC, Travlos A. A Review of Thoracic Outlet Syndrome and the Possible Role of Botulinum Toxin in the Treatment of This Syndrome. Toxins. 2012;4(11):1223-35.
13. Cavallieri F, Galletti S, Fioravanti V, Menozzi E, Contardi S, Valzania F. Botulinum Toxin Treatment for Thoracic Outlet Syndrome Induced by Subclavius Muscle Hypertrophy. NeuroSci. 2021;2(2):135-40.
14. Mashayekh A, Christo PJ, Yousem DM, Pillai JJ. CT-Guided Injection of the Anterior and MiddleScalene Muscles: Technique and Complications. Am J Neuroradiol. 2011;32(3):495-500.
15. Salhan N, Humphries M, Sheth S, DeMesa Ch, Freischlag J. Ultrasound-Guided Anesthetic or BotulinumToxin Injection of the Anterior and Middle Scalene Muscles to Assist With Diagnosis and Treatment of Neurogenic Thoracic Outlet Syndrome. J Vascular Surg. 2016;63(6):218S. DOI: 10.1016/j.jvs.2016.03.365.
16. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55(12 Suppl 5):S29-35.
17. Nájera Losada DC, Pérez Moreno JC, Mendiola de la Osa A. Toxina botulínica en el tratamiento del síndrome de dolor miofascial. Rev Soc Esp Dolor. 2021;28(2):100-10.
18. García Ruiz-Espiga P, Sanz Cartagena P, Martínez Castrillo JC, Ares Pensado B, Avilés Olmos I, Blázquez Estrada S, et al. Mitos y evidencias en el empleo de la Toxina botulínica: neurofarmacología y distonías. Rev Neurol 2018;66(5):163-72.
19. Morales MV, Payares K, Zuluaga A. Conocimientos básicos sobre la toxina botulínica para una utilización terapéutica segura. Artículo de revisión. Rev Col Med Fis Rehab. 2013;23(2):147-59.
20. Gooriah R, Ahmed F. Therapeutic Uses of Botulinum Toxin. J Clin Toxicol. 2015;5(1):225. DOI: 10.4172/2161-0495.1000225
21. Soares A, Andriolo RB, Atallah ÁN, da Silva EMK. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2014;2014(7):CD007533.
22. Torriani M, Gupta R, Donahue DM. Sonographically guided anesthetic injection of anterior scalene muscle for investigation of neurogenic thoracic outlet syndrome. Skeletal Radiol. 2009;38(11):1083-7.
23. Insausti J, Djibilian R, Pellejero EM, Mendiola A. Técnicas en dolor miofascial. Toxina botulínica. Rev Soc Esp Dolor. 2011;18(6):361-5.
24. Dressler D, Altavista MC, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm. 2021;128(3):321-35.